Overall Efficacy — The Core Argument for MAOIs

MAOIs raise serotonin, norepinephrine, and dopamine, a broader mechanism than SSRIs/SNRIs that plausibly underlies their efficacy in anergic and treatment-resistant states (Mann, 2005; Potter, Rudorfer, & Manji, 1991). In the largest network meta-analysis to date (83 RCTs, N=9,609), phenelzine (d=−1.07), tranylcypromine (d=−1.00), isocarboxazid (d=−0.92), and moclobemide (d=−0.88) all significantly outperformed placebo, with effect sizes matching or exceeding TCAs and SSRIs; phenelzine also beat imipramine head-to-head (d=0.35) (Giménez-Palomo et al., 2024). A separate network meta-analysis found phenelzine had the strongest efficacy evidence of any treatment analyzed (Suchting et al., 2021). Notably, oral and transdermal selegiline did not reach significance versus placebo in the 2024 analysis despite the patch holding FDA approval (Food and Drug Administration, 2020; Giménez-Palomo et al., 2024).

TreatmentEffect size vs placebo (d, random effects)d [95% CI]Phenelzine-1.07 [-1.30; -0.84]Pirlindole-1.06 [-1.69; -0.43]Tranylcypromine-1.00 [-1.37; -0.62]Isocarboxazid-0.92 [-1.44; -0.40]Moclobemide-0.88 [-1.12; -0.63]Selegiline (oral)-0.46 [-1.36; 0.44]Selegiline (patch)0.13 [-0.25; 0.50]Amitriptyline-0.90 [-1.35; -0.45]Clomipramine-0.79 [-1.17; -0.40]Imipramine-0.72 [-0.94; -0.50]Nortriptyline-0.57 [-1.07; -0.07]Desipramine-1.31 [-2.94; 0.32]Sertraline-1.26 [-2.14; -0.38]Fluoxetine-0.72 [-1.23; -0.21]Fluvoxamine-0.46 [-1.46; 0.54]Bupropion-0.70 [-6.66; 5.25]CBT-0.58 [-1.51; 0.34]-2-1.5-1-0.500.51< Favours treatmentFavours placebo >
Figure 1. Antidepressant efficacy versus placebo in a network meta-analysis of 83 randomized trials (N = 9,609). Squares show standardized mean differences (Cohen’s d) and whiskers show 95% confidence intervals; negative values favor treatment. Monoamine oxidase inhibitors are highlighted in terracotta. Arrows indicate confidence intervals extending beyond the plotted range. Adapted from Giménez-Palomo et al. (2024).

The MAOI "sweet spots" are atypical depression (phenelzine ~72% response vs 44% imipramine vs 26% placebo) (Birkenhager & Heijnen, 2024; Fornaro et al., 2025), treatment resistant depression (tranylcypromine ~58% response) (Birkenhager & Heijnen, 2024), and anergic/melancholic depression (Ulrich et al., 2020).

Pros and Cons at a Glance

AdvantagesDisadvantagesReferences
Broad monoaminergic mechanismTyramine-mediated hypertensive crisis (irreversible agents)Birkenhager & Heijnen, 2024; Mann, 2005; Van den Eynde, Gillman, & Blackwell, 2022
Superior in atypical depression vs TCAs/placeboSerotonin syndrome with many common drugsBirkenhager & Heijnen, 2024; Fornaro et al., 2025; Gillman, 2005
Effective in TRD when other classes/ECT failLow therapeutic index; life-threatening interactionsBirkenhager & Heijnen, 2024; Brockington et al., 2022; Van den Eynde et al., 2023
Effective in bipolar depression, low switch riskOrthostatic hypotension (most prominent AE)Heijnen et al., 2015; Potter, Rudorfer, & Manji, 1991; Volz & Gleiter, 1998
Efficacy comparable/superior to other classesWeight gain (esp. phenelzine), sexual dysfunction (25–80%), insomniaGiménez-Palomo et al., 2024; Jeste et al., 2022; Nihalani et al., 2012; Remick, Froese, & Keller, 1989
Transdermal selegiline/moclobemide reduce diet & interaction burdenMandatory washout periods; complex switchingCitrome, Goldberg, & Portland, 2013; Food and Drug Administration, 2026; Fulton & Benfield, 1996; Potter, Rudorfer, & Manji, 1991

Dietary Restrictions (The Tyramine "Cheese Reaction")

Irreversible MAOIs eliminate the gut MAO-A barrier that normally metabolizes ingested tyramine; unmetabolized tyramine then displaces norepinephrine and triggers abrupt severe hypertension (Food and Drug Administration, 2020; Youdim & Riederer, 2004). Sensitivity rises ~38-fold with tranylcypromine and ~16-fold with phenelzine, so as little as 10–15 mg of tyramine can precipitate a crisis; a content <6 mg per serving is considered safe (Berlin et al., 1989; Bieck et al., 1989; Walker et al., 1996). Foods to avoid include all aged cheeses, air-dried/fermented/cured meats, tap (draft) beer, soy sauce and stored tofu, fava bean pods, concentrated yeast extract (Marmite), and sauerkraut; fresh meats, processed cheeses, bottled/canned beer and wine in moderation, and commercial-chain pizza are generally acceptable (Food and Drug Administration, 2025; Gardner et al., 1996; Shulman & Walker, 1999). The diet must continue 2 weeks after stopping an irreversible agent (Food and Drug Administration, 2025).

Critically, dietary requirements are formulation-dependent: transdermal selegiline at 6 mg/24h requires no diet (no hypertensive crises across 2,553 phase-III patients), though restrictions return at ≥9 mg/24h; moclobemide (reversible RIMA) requires no diet because high tyramine concentrations competitively displace it from MAO-A (Berlin et al., 1989; Food and Drug Administration, 2020; Fulton & Benfield, 1996; Lotufo-Neto, Trivedi, & Thase, 1999).

Download the MAOI Diet Recipe Book (PDF)

Drug Interactions

Two reactions dominate — serotonin syndrome and hypertensive crisis — and MAOIs carried the highest reporting odds ratio for serotonin syndrome of any drug class in FAERS data (ROR 45.99) (Elli, Novella, & Pasina, 2024).

Contraindicated for serotonin-syndrome risk: all SSRIs and SNRIs, serotonergic TCAs (esp. clomipramine), meperidine, dextromethorphan, tramadol/tapentadol, triptans, linezolid, IV methylene blue, bupropion, mirtazapine, and L-tryptophan/SAM-e/St. John's Wort (Bai et al., 2022; Food and Drug Administration, 2025; Gillman, 2005).

Contraindicated for hypertensive risk: sympathomimetics (pseudoephedrine, phenylephrine, ephedrine), amphetamines/methylphenidate, dopamine, levodopa (Food and Drug Administration, 2025; Lu et al., 2026).

A key clinical pearl: morphine, codeine, oxycodone, and buprenorphine are not serotonin reuptake inhibitors and are safe, with morphine the preferred strong analgesic — unlike meperidine and the other phenylpiperidines, which are lethal in combination (Browne & Linter, 1987; Gillman, 2005).

Washout periods are essential: ≥14 days in either direction for most agents, but ≥5 weeks after fluoxetine because of its long-lived active metabolite norfluoxetine; moclobemide needs only ~24 hours (Food and Drug Administration, 2024, 2026; Norman & Burrows, 1995; Potter, Rudorfer, & Manji, 1991).

Bipolar Versus Unipolar Depression

In unipolar depression, MAOIs are third- to fifth-line, reserved for atypical and treatment-resistant cases; VA/DoD 2022 gives a "weak against" for initial use given the low therapeutic index (Brockington et al., 2022; Thase, 2012).

In bipolar depression, tranylcypromine has the strongest MAOI evidence: 81% response vs 48% for imipramine in anergic bipolar depression (Himmelhoch et al., 1991), and a systematic review (4 RCTs, N=145) found 73.7% response vs 27.5% in controls with a lower switch rate (6.3% vs 18.4%) (Heijnen et al., 2015). An exploratory cohort even found MAOIs more effective in bipolar than unipolar depression with no syndromal switches (Kim & Amsterdam, 2023). The manic-switch signal is generally favorable relative to TCAs and venlafaxine — STEP-BD found switching less common on MAOIs, with TCAs highest (OR 7.80) (Truman et al., 2007) — although CANMAT 2018 conservatively rates MAOI switch risk as moderate (++) (Baldessarini, Tondo, & Vázquez, 2019; Yatham et al., 2018). The consistent guideline principle is that in bipolar depression, MAOIs (chiefly tranylcypromine) should be used only with a concurrent mood stabilizer, at later lines, and favored in anergic presentations (Parker, Graham, & Tavella, 2017; Yatham et al., 2018).

Bottom Line

MAOIs are highly effective — arguably among the most effective antidepressants — with a distinctive, under-used niche in atypical, treatment-resistant, and anergic bipolar depression, and a comparatively low switch risk for tranylcypromine (Fornaro et al., 2025; Heijnen et al., 2015; Van den Eynde et al., 2023). Their drawbacks are almost entirely practical and safety-related: the tyramine diet, a heavy interaction burden, and washout requirements. Transdermal selegiline (6 mg/24h) and moclobemide meaningfully mitigate the dietary and interaction hazards at some cost to potency (Citrome, Goldberg, & Portland, 2013; Fulton & Benfield, 1996; Giménez-Palomo et al., 2024). The chief remaining gap is that the populations in which MAOIs shine clinically are the least studied in modern RCTs (Giménez-Palomo et al., 2024; Heijnen et al., 2015).

MAOI Patient FAQ: Safety, Diet & Risks

References

  • Bai, A. D., McKenna, S., Wise, H., Loeb, M., & Gill, S. S. (2022). Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. JAMA Network Open, 5(12), e2247426. https://doi.org/10.1001/jamanetworkopen.2022.47426
  • Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. Molecular Psychiatry, 24(2), 198-217. https://doi.org/10.1038/s41380-018-0044-2
  • Berlin, I., Zimmer, R., Cournot, A., et al. (1989). Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clinical Pharmacology and Therapeutics, 46(3), 344-51. https://doi.org/10.1038/clpt.1989.149
  • Bieck, P. R., Firkusny, L., Schick, C., et al. (1989). Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clinical Pharmacology and Therapeutics, 45(3), 260-9. https://doi.org/10.1038/clpt.1989.26
  • Birkenhager, T. K., & Heijnen, W. T. (2024). Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression. Acta Psychiatrica Scandinavica, 150(6), 497-499. https://doi.org/10.1111/acps.13753
  • Brockington, R., Buelt, A., Capaldi, V., et al. (2022). Management of Major Depressive Disorder (MDD). Department of Veterans Affairs.
  • Browne, B., & Linter, S. (1987). Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment. The British Journal of Psychiatry, 151, 210-2. https://doi.org/10.1192/bjp.151.2.210
  • Citrome, L., Goldberg, J. F., & Portland, K. B. (2013). Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 151(2), 409-417. https://doi.org/10.1016/j.jad.2013.06.027
  • Elli, C., Novella, A., & Pasina, L. (2024). Serotonin syndrome: A pharmacovigilance comparative study of drugs affecting serotonin levels. European Journal of Clinical Pharmacology, 80(2), 231-237. https://doi.org/10.1007/s00228-023-03596-z
  • Food and Drug Administration. (2020). EMSAM. Updated date: 2020-05-15.
  • Food and Drug Administration. (2024). Fluoxetine. Updated date: 2024-12-11.
  • Food and Drug Administration. (2025). Tranylcypromine Sulfate. Updated date: 2025-07-25.
  • Food and Drug Administration. (2026). Phenelzine sulfate. Updated date: 2026-05-21.
  • Fornaro, M., Caiazza, C., Pistone, L., et al. (2025). Pharmacological treatments for atypical depression: A systematic review and network meta-analysis of randomized controlled trials. European Neuropsychopharmacology, 96, 46-57. https://doi.org/10.1016/j.euroneuro.2025.04.003
  • Fulton, B., & Benfield, P. (1996). Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs, 52(3), 450-74. https://doi.org/10.2165/00003495-199652030-00013
  • Gardner, D. M., Shulman, K. I., Walker, S. E., & Tailor, S. A. (1996). The making of a user friendly MAOI diet. The Journal of Clinical Psychiatry, 57(3), 99-104.
  • Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-41. https://doi.org/10.1093/bja/aei210
  • Giménez-Palomo, A., Chamdal, A. K., Gottlieb, N., et al. (2024). Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta-analysis. Acta Psychiatrica Scandinavica, 150(6), 500-515. https://doi.org/10.1111/acps.13728
  • Heijnen, W. T., De Fruyt, J., Wierdsma, A. I., Sienaert, P., & Birkenhäger, T. K. (2015). Efficacy of tranylcypromine in bipolar depression: A systematic review. Journal of Clinical Psychopharmacology, 35(6), 700-5. https://doi.org/10.1097/JCP.0000000000000409
  • Himmelhoch, J. M., Thase, M. E., Mallinger, A. G., & Houck, P. (1991). Tranylcypromine versus imipramine in anergic bipolar depression. The American Journal of Psychiatry, 148(7), 910-6. https://doi.org/10.1176/ajp.148.7.910
  • Jeste, D. V., Lieberman, J. A., Fassler, D., et al. (2022). Diagnostic and statistical manual of mental disorders. American Psychiatric Association.
  • Kim, T. T., & Amsterdam, J. D. (2023). Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study. Acta Psychiatrica Scandinavica, 147(2), 198-204. https://doi.org/10.1111/acps.13518
  • Lotufo-Neto, F., Trivedi, M., & Thase, M. E. (1999). Meta-analysis of the reversible inhibitors of monoamine oxidase type a moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology, 20(3), 226-47. https://doi.org/10.1016/S0893-133X(98)00075-X
  • Lu, Y., Chen, J., Fan, N., et al. (2026). Machine learning models for drug-drug interaction prediction from computational discovery to clinical application. NPJ Digital Medicine, 9(1), 198. https://doi.org/10.1038/s41746-026-02400-3
  • Mann, J. J. (2005). The medical management of depression. The New England Journal of Medicine, 353(17), 1819-34. https://doi.org/10.1056/NEJMra050730
  • Nihalani, N., Schwartz, T. L., Siddiqui, U. A., & Megna, J. L. (2012). Obesity and psychotropics. CNS Neuroscience & Therapeutics, 18(1), 57-63. https://doi.org/10.1111/j.1755-5949.2011.00232.x
  • Norman, T. R., & Burrows, G. D. (1995). A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Drug Safety, 12(1), 46-54. https://doi.org/10.2165/00002018-199512010-00004
  • Parker, G. B., Graham, R. K., & Tavella, G. (2017). Is there consensus across international evidence-based guidelines for the management of bipolar disorder?. Acta Psychiatrica Scandinavica, 135(6), 515-526. https://doi.org/10.1111/acps.12717
  • Potter, W. Z., Rudorfer, M. V., & Manji, H. (1991). The pharmacologic treatment of depression. The New England Journal of Medicine, 325(9), 633-42. https://doi.org/10.1056/NEJM199108293250907
  • Remick, R. A., Froese, C., & Keller, F. D. (1989). Common side effects associated with monoamine oxidase inhibitors. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 13(3-4), 497-504. https://doi.org/10.1016/0278-5846(89)90137-1
  • Shulman, K. I., & Walker, S. E. (1999). Refining the MAOI diet: Tyramine content of pizzas and soy products. The Journal of Clinical Psychiatry, 60(3), 191-3.
  • Suchting, R., Tirumalajaru, V., Gareeb, R., et al. (2021). Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis. Journal of Affective Disorders, 282, 1153-1160. https://doi.org/10.1016/j.jad.2021.01.021
  • Thase, M. E. (2012). MAOIs and depression treatment guidelines. The Journal of Clinical Psychiatry, 73(7), e24. https://doi.org/10.4088/JCP.11096tx4c
  • Truman, C. J., Goldberg, J. F., Ghaemi, S. N., et al. (2007). Self-reported history of manic/hypomanic switch associated with antidepressant use: Data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). The Journal of Clinical Psychiatry, 68(10), 1472-9. https://doi.org/10.4088/jcp.v68n1002
  • Ulrich, S., Ricken, R., Buspavanich, P., Schlattmann, P., & Adli, M. (2020). Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: A systematic review and comprehensive meta-analysis. Journal of Clinical Psychopharmacology, 40(1), 63-74. https://doi.org/10.1097/JCP.0000000000001153
  • Van den Eynde, V., Abdelmoemin, W. R., Abraham, M. M., et al. (2023). The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectrums, 28(4), 427-440. https://doi.org/10.1017/S1092852922000906
  • Van den Eynde, V., Gillman, P. K., & Blackwell, B. B. (2022). The prescriber's guide to the MAOI diet-thinking through tyramine troubles. Psychopharmacology Bulletin, 52(2), 73-116.
  • Volz, H. P., & Gleiter, C. H. (1998). Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs & Aging, 13(5), 341-55. https://doi.org/10.2165/00002512-199813050-00002
  • Walker, S. E., Shulman, K. I., Tailor, S. A., & Gardner, D. (1996). Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. Journal of Clinical Psychopharmacology, 16(5), 383-8. https://doi.org/10.1097/00004714-199610000-00007
  • Yatham, L. N., Kennedy, S. H., Parikh, S. V., et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609
  • Youdim, M. B., & Riederer, P. F. (2004). A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology, 63(7 Suppl 2), S32-5. https://doi.org/10.1212/wnl.63.7_suppl_2.s32